Breakthrough Therapy designation for Padcev plus Keytruda combo

20 February 2020
seattle_genetics_big

Antibody-drug conjugate (ADC) specialist Seattle Genetics (Nasdaq: SGEN) and co-developer Astellas Pharma (TYO: 4503) have picked up a Breakthrough Therapy designation for Padcev (enfortumab vedotin-ejfv).

The designation applies to a combination therapy of Padcev, the firm’s second approved ADC, and Merck & Co’s (NYSE: MRK) blockbuster checkpoint inhibitor Keytruda (pembrolizumab) in bladder cancer.

The firms are developing the treatment for people with unresectable locally-advanced or metastatic urothelial cancer who are ineligible for first-line cisplatin-based chemo.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical